Summary: Bronchial carcinoid tumor, while rare, remains the most common primary malignant lung tumor in children. We present a retrospective analysis of 7 patients with typical bronchial carcinoid tumors diagnosed at 2 pediatric tertiary care referral centers between 1990 and 2014. The most common presenting symptom was pneumonia, followed by respiratory distress. Somatostatin scans were performed in selected patients. All patients had negative resection margin following surgery and were alive without disease at last follow-up. Typical carcinoid tumors have a good prognosis following definitive surgical resection. A review of published literature on pediatric bronchial carcinoid tumors is provided.
B
ronchial carcinoid tumors are the most common primary malignant lung tumors in children, comprising between 63% and 80% of all cases. 1 These tumors arise from bronchial mucosal neuroendocrine cells, which have the ability to secrete amines and peptides. The term "carcinoid" distinguishes these well-differentiated neuroendocrine tumors from their poorly differentiated counterparts, which include large-cell neuroendocrine carcinomas and small-cell lung cancer.
Bronchial carcinoids are further subdivided based on malignancy potential, with a majority of pediatric patients presenting with typical carcinoids which have low malignant potential. Atypical carcinoids are less common in the pediatric population and have an intermediate malignancy potential. Unlike their poorly differentiated counterparts, bronchial carcinoids in children have a good prognosis when appropriately treated. Recent data from the National Cancer Database showed a 5 year overall survival of 95%. 1 Given the relative rarity of malignant pulmonary tumors in children, the majority of information about bronchial carcinoid tumors comes from adult literature. Here we present a retrospective analysis of a cohort of pediatric patients with bronchial carcinoids from 2 institutions over a 25-year period and review the published literature.
MATERIALS AND METHODS
All patients younger than 21 years of age diagnosed with bronchial carcinoid between 1990 and 2014 at Texas Children's Hospital and Children's Hospital Los Angeles were identified from the pathology database. Their presenting symptoms, clinical features, treatment, and outcome were obtained by review of medical records. The institutional review boards at both institutions approved the conduct of the study.
RESULTS
A total of 7 pediatric patients with bronchial carcinoids were identified. The patients ranged in age from 9 to 16 years with a mean age of 12.7 years (Table 1) . Three patients were male and 4 were female. The most common presenting symptom was pneumonia in 3 patients. Two patients exhibited respiratory distress (tachypnea, wheezing, or difficulty breathing), and 1 presented with hemoptysis. Only 1 patient presented with symptoms of Cushing syndrome because of ectopic adrenocorticotropic hormone production by the tumor. Of note, patient 1 was diagnosed with multiple episodes of wheezing over 2 years before receiving her diagnosis, and patient 3 was treated for persistent cough and pneumonia for a month before diagnosis. Three patients were noted to have decreased breath sounds on 1 side during physical examination.
Five tumors occurred in the right bronchi and 2 in the left. Four patients underwent preoperative computed tomography scans, none of which showed evidence of mediastinal lymphadenopathy. Three patients underwent somatostatin scans which showed uptake in all three. Distal bronchopathy because of obstruction was common in this series and included 2 patients with hyperinflation and air trapping, 2 with atelectasis, and 1 with pneumothorax and pneumomediastinum. Endobronchial biopsy was performed in 4 cases before definitive surgery. All patients were treated by surgical resection. Pathologic examination revealed typical carcinoid tumors in all patients. Lymph nodes were sampled in 6 patients, 3 of whom had a positive lymph node. The majority of patients had negative margins after surgery, with the exception of 1 patient with minimal residual disease, and one whose data was unavailable. Genetic testing for MEN1 gene mutation performed in 2 patients was negative. Bronchial stenosis requiring balloon dilatation developed in 1 patient. All patients were alive without disease at last follow-up (median, 49 mo; range, 3 to 67 mo).
DISCUSSION
Bronchial carcinoid is the most common primary malignant lung tumor in children; however, it remains a rare diagnosis because of the low incidence of childhood lung malignancies. Published literature of pediatric bronchial carcinoid is summarized in Table 2 . Children typically present with respiratory symptoms including cough, chest pain, wheezing, hemoptysis, and difficulty breathing. 5, 8, 9 Similar to patient 1 in our series, misdiagnosis as asthma is common given the nonspecific and persistent respiratory symptoms. Endobronchial obstruction by the tumor can lead to a unilateral lobar consolidation on chest radiograph, commonly interpreted as pneumonia; the presence of a tumor may only become apparent after investigations for these recurrent episodes. Rarely, children can present with Cushing syndrome because of ectopic adrenocorticotropic hormone secretion, as noted in patient 4. 18 Carcinoid syndrome, caused by the release of systemic vasoactive substances that cause symptoms including wheezing, flushing, palpitations, and diarrhea, is rare in the absence of metastases. The most common site of metastasis is the intrathoracic lymph nodes, although liver and skeletal metastases have been described in children. 12 Bronchial carcinoid is usually detected as a mass on chest imaging performed for respiratory symptoms. 16, 19 Typical carcinoids tend to be more centrally located, whereas atypical carcinoids tend to be located peripherally. Diagnosis is generally confirmed by histopathologic examination following endobronchial biopsy. When there is concern for metastasis, an octreotide scan may be used to identify metastatic lesions. Metaiodobenzylguanidine scans and positron emission tomography scans are options for patients with negative octreotide scans, although recent adult data found low metaiodobenzylguanidine sensitivity for detecting pulmonary carcinoids, suggesting positron emission tomography may be preferable. 19 Testing for multiple endocrine neoplasia type I (MEN-1) should be considered, as bronchial carcinoid occurs in 5% of these patients. 20 Morphologically, typical carcinoid is characterized by highly organized architecture and <2 mitoses per 10 highpower fields (HPFs) and the absence of necrosis. Atypical carcinoid, by contrast, has greater mitotic activity (2 to 10 mitoses/10 HPF), and/or the presence of necrosis. Both tumor types may be positive for neuroendocrine markers such as chromogranin A and synaptophysin. Ki-67 index may help differentiate high-grade tumors and low-grade tumors, and has been shown to be associated with length of overall survival in adults. 19 For localized tumors, complete surgical resection is the treatment of choice. Lymph node resection is recommended for atypical carcinoid given its increased malignancy potential. The effect of lymph node resection on overall survival for typical bronchial carcinoid in pediatrics has not been clearly defined; however, multiple series have shown that lymphatic spread occurs in up to 20% of pediatric patients of both histologies. 1, 5, 9, 17 Given this information, we believe that lymph node resection should be performed for all enlarged nodes and lymph node sampling should be considered in other patients.
At this time, there is no curative treatment for metastatic disease. Somatostatin analogues and interferon α have been used in advanced disease in adults without significant benefit. Temozolomide monotherapy achieved partial responses in 14% and stable disease in 52% of 31 adult patients with progressive metastatic bronchial carcinoid. 21 Median progression-free survival was 5.3 months and median overall survival was 23.2 months from the start of temozolomide.
Prognosis for patients with typical carcinoid is excellent, with > 90% survival. 22 There is a paucity of data on atypical carcinoid in children, but 2 of 8 patients died in a reported series. 12 A study of 247 adults with atypical carcinoid found that tumor size, lymph nodal metastatic involvement, pathologic staging, mitotic index, and Ki-67 (MIB-1) were all significant in the univariate analysis as prognostic factors; lymph node metastasis was significant in the multivariate analysis. 23 No follow-up is necessary for node negative localized completely resected typical carcinoid tumors. 24, 25 For others, computed tomography scan of the neck and chest every 6 to 12 months is appropriate given the indolent nature of these tumors. Recent data suggest that unlike their adult counterparts, pediatric patients with carcinoid tumors are not at increased risk for second primary malignancies, although this warrants further investigation. 26 In summary, pediatric typical 
